Switch theme
Sign up to access all valuation multiples
Dynavax Technologies Corp is a biopharmaceutical company. The company focuses on leveraging the power of the body's innate and adaptive immune responses through toll-like receptor stimulation. Its current product candidates are being investigated for use in multiple cancer indications as a vaccine for the prevention of HEPLISAV-B (Hepatitis B Vaccine (Recombinant), Adjuvanted), operates in the business segment of discovery, development, and commercialization of novel vaccines. Its Toll-like Receptor Immune Modulation Platform technology plays a vital role in innate immunity and subsequent adaptive immunity. The company generates the vast majority of its revenue from the sale of its CpG 1018 product and HEPLISAV-B.
1996
405
LTM Revenue $287M
LTM EBITDA $45.4M
$1.3B
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Dynavax has a last 12-month revenue of $287M and a last 12-month EBITDA of $45.4M.
In the most recent fiscal year, Dynavax achieved revenue of $277M and an EBITDA of $45.7M.
Dynavax expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Dynavax valuation multiples based on analyst estimates| FY 2023 | FY 2024 | FY 2025 | LTM | NTM | |
|---|---|---|---|---|---|
| Revenue | $232M | $277M | XXX | XXX | XXX |
| Gross Profit | $461M | $182M | XXX | XXX | XXX |
| Gross Margin | 198% | 66% | XXX | XXX | XXX |
| EBITDA | $9.7M | $45.7M | XXX | XXX | XXX |
| EBITDA Margin | 4% | 16% | XXX | XXX | XXX |
| Net Profit | $293M | -$6.4M | XXX | XXX | XXX |
| Net Margin | 126% | -2% | XXX | XXX | XXX |
| Net Debt | $19.6M | $72.4M | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of March 14, 2025, Dynavax's stock price is $14.
Dynavax has current market cap of $1.7B, and EV of $1.3B.
See Dynavax trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $1.3B | $1.7B | XXX | XXX | XXX | XXX | $0.23 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Sign UpAs of March 14, 2025, Dynavax has market cap of $1.7B and EV of $1.3B.
Dynavax's trades at 4.4x LTM EV/Revenue multiple, and 27.8x LTM EBITDA.
Analysts estimate Dynavax's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See valuation multiples for Dynavax and 10K+ public comps| FY 2024 | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|
| EV | $1.3B | XXX | XXX | XXX |
| EV/Revenue | 4.5x | XXX | XXX | XXX |
| EV/EBITDA | 27.6x | XXX | XXX | XXX |
| P/E | 63.0x | XXX | XXX | XXX |
| P/E/Growth | 0.8x | XXX | XXX | XXX |
| EV/FCF | 21.0x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Sign UpDynavax's NTM/LTM revenue growth is 18%
Dynavax's revenue per employee for the last fiscal year averaged $0.7M, while opex per employee averaged $0.6M for the same period.
Over next 12 months, Dynavax's ratio of sales and marketing spend to revenue is estimated to be XXX , while its R&D spend to revenue to be XXX .
Analysts estimate Dynavax's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See operational valuation multiples for Dynavax and other 10K+ public comps| FY 2024 | NTM | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|---|
| Revenue Growth | 19% | XXX | XXX | XXX | XXX |
| EBITDA Margin | 16% | XXX | XXX | XXX | XXX |
| EBITDA Growth | 373% | XXX | XXX | XXX | XXX |
| Rule of 40 (SaaS-only) | 34% | XXX | XXX | XXX | XXX |
| Revenue per Employee | $0.7M | XXX | XXX | XXX | XXX |
| Opex per Employee | $0.6M | XXX | XXX | XXX | XXX |
| S&M Expenses to Revenue | n/a | XXX | XXX | XXX | XXX |
| G&A Expenses to Revenue | 61% | XXX | XXX | XXX | XXX |
| R&D Expenses to Revenue | 22% | XXX | XXX | XXX | XXX |
| Opex to Revenue | 84% | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| Armata Pharmaceuticals | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Dynavax acquired XXX companies to date.
Last acquisition by Dynavax was XXXXXXXX, XXXXX XXXXX XXXXXX . Dynavax acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Sign Up| When was Dynavax founded? | Dynavax was founded in 1996. |
| Where is Dynavax headquartered? | Dynavax is headquartered in United States of America. |
| How many employees does Dynavax have? | As of today, Dynavax has 405 employees. |
| Who is the CEO of Dynavax? | Dynavax's CEO is Mr. Ryan Spencer. |
| Is Dynavax publicy listed? | Yes, Dynavax is a public company listed on NAS. |
| What is the stock symbol of Dynavax? | Dynavax trades under DVAX ticker. |
| When did Dynavax go public? | Dynavax went public in 2004. |
| Who are competitors of Dynavax? | Similar companies to Dynavax include e.g. Julphar, Galapagos, Pharming, Vivoryon Therapeutics. |
| What is the current market cap of Dynavax? | Dynavax's current market cap is $1.7B |
| What is the current revenue of Dynavax? | Dynavax's last 12-month revenue is $287M. |
| What is the current EBITDA of Dynavax? | Dynavax's last 12-month EBITDA is $45.4M. |
| What is the current EV/Revenue multiple of Dynavax? | Current revenue multiple of Dynavax is 4.4x. |
| What is the current EV/EBITDA multiple of Dynavax? | Current EBITDA multiple of Dynavax is 27.8x. |
| What is the current revenue growth of Dynavax? | Dynavax revenue growth between 2023 and 2024 was 19%. |
| Is Dynavax profitable? | Yes, Dynavax is EBITDA-positive (as of the last 12 months). |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
